Patents by Inventor Brenda A. Kellogg
Brenda A. Kellogg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230105468Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: ApplicationFiled: October 12, 2022Publication date: April 6, 2023Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. CHARI
-
Patent number: 11498979Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: September 24, 2020Date of Patent: November 15, 2022Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. Chari
-
Publication number: 20210163625Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: ApplicationFiled: September 24, 2020Publication date: June 3, 2021Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. CHARI
-
Patent number: 10815309Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: February 1, 2019Date of Patent: October 27, 2020Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. Chari
-
Publication number: 20190263935Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: February 1, 2019Publication date: August 29, 2019Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. Chari
-
Patent number: 10233257Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: September 1, 2017Date of Patent: March 19, 2019Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Publication number: 20180079828Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: September 1, 2017Publication date: March 22, 2018Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V.J. Chari
-
Patent number: 9771432Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: May 27, 2016Date of Patent: September 26, 2017Assignee: IMMUNOGEN, INC.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Publication number: 20170002096Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: May 27, 2016Publication date: January 5, 2017Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. J. CHARI
-
Patent number: 9376500Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: December 3, 2013Date of Patent: June 28, 2016Assignee: ImmunoGen, Inc.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Publication number: 20140179906Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: December 3, 2013Publication date: June 26, 2014Applicant: ImmunoGen, Inc.Inventors: Brenda A. KELLOGG, Rajeeva SINGH, Ravi V. J. CHARI
-
Patent number: 8624003Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.Type: GrantFiled: June 3, 2010Date of Patent: January 7, 2014Assignee: ImmunoGen, Inc.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
-
Publication number: 20110003969Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups.Type: ApplicationFiled: June 3, 2010Publication date: January 6, 2011Applicant: Immunogen Inc.Inventors: Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari